Fig. 1
From: Drugging the epigenome in the age of precision medicine
Precision epigenomic therapies have the potential to improve efficacy and tolerability. Early epigenomic therapies are limited by a lack of specificity, leading to off-target effects and more narrow therapeutic utility, as well as more limited tunability and durability. Precision therapies that act at discrete, specific loci should mitigate these challenges while delivering on the therapeutic promise of epigenomic modulation